The mammalian bombesin receptor family comprises three G protein-coupled heptahelical
receptors: the neuromedin B (NMB) receptor (BB 1), the gastrin-releasing peptide (GRP) …

Over the last two decades, several lines of experimental evidence have suggested that the
gastrin-releasing peptide (GRP) may act as a growth factor in many types of cancer. For that …

Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer
(SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular …

We review the molecular pathogenesis of lung cancer including alterations in dominant
oncogenes, recessive oncogenes/tumor suppressor genes, alterations in growth regulatory …

Over the past 20 years, abundant evidence has been collected to suggest that gastrin-
releasing peptide (GRP) and its receptors play an important role in the development of a …

Lung cancer is the largest cancer killer of men and women in the united states. In addition to
the progress made from antismoking primary prevention measures, new tools to help treat …

Gastrin-releasing peptide (GRP) receptor scintigraphy could allow prediction of response to
GRP receptor-targeted treatment options, early non-invasive diagnosis and in vivo …

Introduction: Despite remarkable advances in tumor treatment, many patients still die from
common tumors (breast, prostate, lung, CNS, colon, and pancreas), and thus, new …

It has been hypothesised that clinically evident lung cancers have accumulated many
different genetic or epigenetic abnormalities in oncogenes and/or tumour suppressor genes …

Over the past 100 years, our understanding of the pathogenesis of lung cancer has
advanced impressively. Environmental carcinogens and a gene locus determining …